Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta …
Background Long‐acting bronchodilators such as long‐acting β‐agonist (LABA), long‐
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …
Long-acting muscarinic antagonists
AS Melani - Expert review of clinical pharmacology, 2015 - Taylor & Francis
Chronic obstructive pulmonary disease (COPD) is a major cause of death and disability
worldwide. Inhaled bronchodilators are the mainstay of COPD pharmacological treatment …
worldwide. Inhaled bronchodilators are the mainstay of COPD pharmacological treatment …
Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized …
GJ Feldman, AR Sousa, DA Lipson, L Tombs… - Advances in …, 2017 - Springer
Introduction We report the results of the first direct comparison of the once-daily fixed-dose
long-acting muscarinic antagonist/long-acting β 2-agonist (LAMA/LABA) combinations …
long-acting muscarinic antagonist/long-acting β 2-agonist (LAMA/LABA) combinations …
[HTML][HTML] Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD
Background Long-acting muscarinic antagonist (LAMA)/long-acting β 2-agonist (LABA)
combinations are a treatment option for patients with COPD who continue to have symptoms …
combinations are a treatment option for patients with COPD who continue to have symptoms …
Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN …
PA Frith, PJ Thompson, R Ratnavadivel, CL Chang… - Thorax, 2015 - thorax.bmj.com
Background The optimal use of various therapeutic combinations for moderate/severe
chronic obstructive pulmonary disease (COPD) is unclear. The GLISTEN trial compared the …
chronic obstructive pulmonary disease (COPD) is unclear. The GLISTEN trial compared the …
Pharmacology, toxicology and clinical safety of glycopyrrolate
M Chabicovsky, S Winkler, M Soeberdt, A Kilic… - Toxicology and applied …, 2019 - Elsevier
The clinical use of the anticholinergic glycopyrrolate dates back to the early 1960s when it
was first approved in the US Since then, oral and inhalation formulations have been …
was first approved in the US Since then, oral and inhalation formulations have been …
Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends
P Montuschi, G Ciabattoni - Journal of medicinal chemistry, 2015 - ACS Publications
Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and
long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological …
long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological …
Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
MIA Aziz, LE Tan, DBC Wu, F Pearce… - … journal of chronic …, 2018 - Taylor & Francis
Purpose To assess the comparative efficacy of short-acting muscarinic antagonists (SAMAs),
long-acting muscarinic antagonists (LAMAs), LAMA in combination with long-acting beta …
long-acting muscarinic antagonists (LAMAs), LAMA in combination with long-acting beta …
[PDF][PDF] Revised (2018) COPD clinical practice guideline of the Korean Academy of Tuberculosis and Respiratory Disease: a summary
YB Park, CK Rhee, HK Yoon, YM Oh… - Tuberculosis and …, 2018 - synapse.koreamed.org
Chronic obstructive pulmonary disease (COPD) results in high morbidity and mortality
among patients nationally and globally. The Korean clinical practice guideline for COPD …
among patients nationally and globally. The Korean clinical practice guideline for COPD …
Correlations between FEV1 and patient-reported outcomes: a pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease
JF Donohue, PW Jones, C Bartels, J Marvel… - Pulmonary …, 2018 - Elsevier
Background In clinical trials of inhaled bronchodilators, chronic obstructive pulmonary
disease (COPD) guidelines recommend that patient-reported outcomes (PROs) are …
disease (COPD) guidelines recommend that patient-reported outcomes (PROs) are …